Trials / Completed
CompletedNCT00957203
Long-Term Safety Study of KW-6002 (Istradefylline) in Parkinson's Disease Patients
Long-Term Safety Study of KW-6002 (Istradefylline) in the Treatment of Parkinson's Disease (Phase 3)
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 308 (actual)
- Sponsor
- Kyowa Kirin Co., Ltd. · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
Patients with Parkinson's disease who completed the prior double-blind study 6002-009 are eligible to enter into this long-term study. The purpose of this study is to evaluate the safety and efficacy of KW-6002 administered long-term in patients with advanced Parkinson's disease treated with levodopa.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Istradefylline | Oral istradefylline (KW-6002) 20 or 40 mg once daily |
Timeline
- Start date
- 2009-10-01
- Primary completion
- 2011-09-01
- Completion
- 2012-03-01
- First posted
- 2009-08-12
- Last updated
- 2012-08-31
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT00957203. Inclusion in this directory is not an endorsement.